John E Dick
Overview
Explore the profile of John E Dick including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
159
Citations
19628
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Itkin T, Houghton S, Schreiner R, Lin Y, Badwe C, Voisin V, et al.
Nat Immunol
. 2025 Feb;
26(3):378-390.
PMID: 40000903
Transition between activation and quiescence states in hematopoietic stem and progenitor cells (HSPCs) is tightly governed by cell-intrinsic means and microenvironmental co-adaptation. Although this balance is fundamental for lifelong hematopoiesis...
2.
Araujo J, Wagenblast E, Voisin V, McLeod J, Gan O, Bansal S, et al.
Blood
. 2025 Jan;
PMID: 39841016
Leukemic stem cells (LSCs) fuel acute myeloid leukemia (AML) growth and relapse, but therapies tailored towards eradicating LSCs without harming normal hematopoietic stem cells (HSCs) are lacking. FLT3 is considered...
3.
Gower M, Li X, Aguilar-Navarro A, Lin B, Fernandez M, Edun G, et al.
Sci Transl Med
. 2025 Jan;
17(779):eadr2012.
PMID: 39742502
T-lineage acute lymphoblastic leukemia (ALL) is an aggressive cancer comprising diverse subtypes that are challenging to stratify using conventional immunophenotyping. To gain insights into subset-specific therapeutic vulnerabilities, we performed an...
4.
Boutzen H, Murison A, Oriecuia A, Bansal S, Arlidge C, Wang J, et al.
Leukemia
. 2024 Aug;
38(10):2090-2101.
PMID: 39169113
The leukemia stem cell (LSC) compartment is a complex reservoir fueling disease progression in acute myeloid leukemia (AML). The existence of heterogeneity within this compartment is well documented but prior...
5.
Scolari F, Brahmbhatt D, Abelson S, Lee D, Kim R, Pedarzadeh A, et al.
Eur J Heart Fail
. 2024 Aug;
26(10):2193-2202.
PMID: 39091134
Aims: The heterogeneous phenotype of hypertrophic cardiomyopathy (HCM) is still not fully understood. Clonal haematopoiesis (CH) is emerging as a cardiovascular risk factor potentially associated with adverse clinical events. The...
6.
Jakobsen N, Turkalj S, Zeng A, Stoilova B, Metzner M, Rahmig S, et al.
Cell Stem Cell
. 2024 Jun;
31(8):1127-1144.e17.
PMID: 38917807
Clonal hematopoiesis (CH) arises when hematopoietic stem cells (HSCs) acquire mutations, most frequently in the DNMT3A and TET2 genes, conferring a competitive advantage through mechanisms that remain unclear. To gain...
7.
Johnson C, Williams M, Sham K, Belluschi S, Ma W, Wang X, et al.
Blood
. 2024 May;
144(7):729-741.
PMID: 38805639
Loss of long-term hematopoietic stem cell (LT-HSC) function ex vivo hampers the success of clinical protocols that rely on culture. However, the kinetics and mechanisms through which this occurs remain...
8.
Hosseini M, Voisin V, Chegini A, Varesi A, Cathelin S, Manikoth Ayyathan D, et al.
Res Sq
. 2024 Feb;
PMID: 38405837
Clonal hematopoiesis (CH) arises when a hematopoietic stem cell (HSC) acquires a mutation that confers a competitive advantage over wild-type (WT) HSCs, resulting in its clonal expansion. Individuals with CH...
9.
Zeng A, Iacobucci I, Shah S, Mitchell A, Wong G, Bansal S, et al.
bioRxiv
. 2024 Jan;
PMID: 38234771
In acute myeloid leukemia (AML), genetic mutations distort hematopoietic differentiation, resulting in the accumulation of leukemic blasts. Yet, it remains unclear how these mutations intersect with cellular origins and whether...
10.
Iacobucci I, Zeng A, Gao Q, Garcia-Prat L, Baviskar P, Shah S, et al.
bioRxiv
. 2023 Dec;
PMID: 38106088
Sequencing of bulk tumor populations has improved genetic classification and risk assessment of B-ALL, but does not directly examine intratumor heterogeneity or infer leukemia cellular origins. We profiled 89 B-ALL...